Overview
AAV9 Gene Therapy in Type II GM1 Gangliosidosis — A Phase 1–2 Trial
Mar 26, 2026DOI: 10.1056/nejmoa2510935Original ArticleNEJM
Written by: Connor J. Lewis, B.S.Precilla D’Souza, D.N.P.Jean M. Johnston, M.S.Maria T. Acosta, M.D.Cristan Farmer, Ph.D.Eva H. Baker, M.D., Ph.D.Anna Crowell, B.A.Yoliann Mojica, M.S.Sumaiya Ashraf, M.S.Lisa Joseph, Ph.D.Gilbert Vézina, M.D.Zenaide Quezado, M.D.Muhammad H. Yousef, M.D.Zeynep Vardar, M.D.Mohammed Salman Shazeeb, Ph.D.Manuela Corti, Ph.D.Meghan Blackwood, B.S.Kirsten Coleman, M.B.A.Rita Batista, Ph.D.Audrey Thurm, Ph.D.Erika De Boever, D.D.S., Ph.D.William A. Gahl, M.D., Ph.D.Barry J. Byrne, M.D., Ph.D.Terence R. Flotte, M.D.Xuntian Jiang, Ph.D.Amanda L. Gross, Ph.D.Allison M. Keeler, Ph.D.Heather Gray-Edwards, D.V.M., Ph.D.Douglas R. Martin, Ph.D.Miguel Sena-Esteves, Ph.D.Cynthia J. Tifft, M.D., Ph.D.
Find these authors on Roon
MA
Child Neurology · CNMC
